

DAWN M. CARLSON, MD, MPH

Professional Experience:

- | | |
|---------------------|---|
| 1/23/2023—current | Vice President, Neuroscience Development
AbbVie |
| | <ul style="list-style-type: none">• Responsible for management of TA clinical research staff• Responsible for management of portfolio of Neuroscience assets, including on market and pipeline compounds |
| 1/1/2019–1/22/23 | Vice President, Clinical Pharmacology and Pharmacometrics
AbbVie |
| | <ul style="list-style-type: none">• Responsible for management of clinical pharmacologists, pharmacokineticists, and clinical research unit staff for all AbbVie systemic assets |
| 8/1/2016–12/31/2018 | Vice President, General Medicine Development
AbbVie |
| | <ul style="list-style-type: none">• Responsible for management of TA clinical research staff• Responsible for management of portfolio of General Medicine assets, including on market and pipeline compounds |
| 9/14/2015–7/31/2016 | Executive Medical Director, Oncology Solid Tumors
AbbVie |
| | <ul style="list-style-type: none">• Direct and manage Group Medical Directors and clinical research staff across the TA• Ensure robust clinical development plans and clinical study deliverables• Dotted line management of Hematology Group Medical Directors and clinical research staff• Represent clinical research TA on Protocol Simplification Committee• Co-lead of Clinical Research Forum for Group and Executive Medical and Scientific Directors |
| 4/1/2015–9/11/2015 | Executive Medical Director, Humira Rheumatology, Dermatology,
and Gastroenterology Development Teams
AbbVie |
| | <ul style="list-style-type: none">• Direct and manage Group Medical Directors and clinical research staff across the TA• Ensure robust clinical development plans and clinical study deliverables• Represent clinical research TA on Protocol Simplification Committee• Co-lead of Clinical Research Forum for Group and Executive Medical and Scientific Directors |
| 1/1/2013–3/31/2015 | Project Director, Immunology, Global Pharmaceutical Research
and Development, AbbVie |
| 1/1/2013–2/2014 | Humira Dermatology Project Team |
| 1/1/2013–8/2013 | Humira Rheumatology Project Team
Creon Project Team |
| | <ul style="list-style-type: none">• Direct and manage matrixed cross functional teams responsible for pharmaceutical development of Humira Rheumatology (rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis), Humira Dermatology (psoriasis and hidradenitis suppurativa), Creon (pancreatic enzyme replacement therapy (PERT))• Manage medical and scientific directors |

- Work with joint development committees including partnered companies for Creon responsible for conduct of postmarketing commitments for PERT, collaboration with Abbott on new pancreatin formulation
- Lead team through Phase 3 studies for Hidradenitis Suppurativa
- Leading team through sBLA submissions for non-radiographic axial spondyloarthritis (US and EU), juvenile idiopathic arthritis 2 -4 years old (US and EU), psoriasis (China), pediatric psoriasis (EU), hidradenitis suppurativa (US and EU)
- Key participant in FDA Advisory Committee Meeting for Humira non-radiographic axial spondyloarthritis
- Mentor for Pharmaceutical Development Program participant

10/1/2008–4/8/2012

Project Director
Oncology Development
Global Pharmaceutical Research & Development
Abbott

- Responsible for oversight of the multiple oncology assets across all phases of development, including small molecules and antibody development programs in solid tumors and hematologic malignancies
 - Key participant in interactions with FDA, SFDA, PMDA, EMA, KFDA

4/10/2006–9/30/2008

Senior Medical Director
Dyslipidemia Global Project Team
Global Pharmaceutical Research & Development
Abbott

- Responsible for conduct and review of Phase 3 studies
- Key contributor to NDA submission 12/07

7/31/2003–4/7/2006

Medical Director, Oncology Group
Global Pharmaceutical Research & Development
Abbott

- Responsible for conduct and review of Phase 2 anti-angiogenic compound
- Prepared and reviewed regulatory submissions, interacted with FDA & EMEA
- Prepared IND and Phase 1 protocols for tyrosine kinase inhibitor; initiated two Phase 1 trials
- Key member of committee convened to assess need for risk management plan for a Phase 3 oncology product
- Member of team that developed proposal for Risk Management Office
- Member of committee developing approach to premarketing product safety assessment across clinical studies

3/9/1998–7/30/2003

Medical Director, Postmarketing Safety Evaluation
Global Medical Services
Global Pharmaceutical Research & Development
Abbott

- Managed and directed the activities of seven safety physicians supporting worldwide medical pharmacovigilance for pharmaceutical products
- Provided postmarketing medical review of adverse event reports

- Prepared regulatory submissions for proposed product label revisions
- Coordinated and authored responses to global regulatory queries regarding product safety issues
- Served as role model and primary trainer for new physician hires in postmarketing safety surveillance

7/1993–3/1998

Associate Professor of Medicine & Neurology
Loyola University Medical Center
Edward Hines Veterans Administration Center
Maywood, IL

- Secured grant from Veterans Research Advisory Group for investigation of upper airway muscle physiology in obstructive sleep apnea
- Successfully recruited subjects to complete two independent research studies and participated in recruitment of subjects for ICU study of nitric oxide delivery system in ARDS
- Prepared and presented results of original research at international meetings
- Presented regular didactic lectures and grand rounds to diverse audiences
- Directly cared for inpatients in ICU and general medical wards, and outpatients in pulmonary and sleep clinics
- Trained medical students, internal medicine residents, and pulmonary fellows
 - Nominated for Golden Apple teaching award

7/1989–6/1990

Staff Physician, Internal Medicine
Westside VA Hospital, Chicago, IL

- Created Women's Health Clinic
- Supervised internal medicine resident outpatient clinic
- Developed and wrote handbook for General Internal Medicine Clinic Residents

Education and Training:

6/2000–5/2003

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
M.P.H. Epidemiology and Biostatistics

1990–1993

University of Illinois Hospital, Chicago, IL
Westside VA Hospital
Fellow, Pulmonary and Critical Care Medicine
Sleep Medicine Training

1986–1989

University of Illinois Hospital, Chicago, IL
Resident, Internal Medicine

1982–1986

University of Illinois College of Medicine, Chicago, IL
M.D.

1978–1982

University of Illinois, Champaign, IL
B.S. Microbiology

Licensure/Certification:

2003	Board Recertification, American Board of Internal Medicine Subspecialty of Critical Care Medicine (through 2013)
2002	Board Recertification, American Board of Internal Medicine Subspecialty of Pulmonary Medicine (through 2012)
1995	Diplomate, American Board of Sleep Medicine
1992	Fellow, American College of Chest Physicians
1989	Board Certification, American Board of Internal Medicine (valid indefinitely)
1987	Licensed Physician & Surgeon, State of Illinois (active)
1986	Diplomate, National Board of Medical Examiners

Professional Affiliations

American College of Chest Physicians (ACCP) through 2009
Steering Committee Member of ACCP Members in Industry Network
Vice Chair, 2006-2008
Delta Omega Honorary Society for Public Health
American Society Clinical Pharmacokinetics and Therapeutics 2019
Industry Representative (non-voting) to the FDA PADAC Advisory Committee 2019-current

Publications

Carlson DM, Carley DW, Önal E, Lopata M, Basner RC. Acoustically induced cortical arousal increases phasic pharyngeal muscle and diaphragm EMG in NREM sleep. *Journal of Applied Physiology*. 76:1553-1559, 1994.

Carlson DM, Önal E, Carley DW, Lopata M, Basner RC. Palatal muscle electromyogram activity in obstructive sleep apnea. *American Journal of Respiratory and Critical Care Medicine*. 152:1022-1027, 1995.

Carlson DM, Steinberg JL, Gordon G. Targeting the unmet medical need: the Abbott Laboratories oncology approach. *Clinical Advances in Hematology & Oncology*. 3:703-712, 2005.

Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric acid in patients with type 2 diabetes mellitus. *Cardiovasc Drugs Ther*. 2011 Feb;25(1):47-57.

Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, and Jones PH. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. *Am J Cardiovasc Drugs* 2010; 10 (3): 175-186.

Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia – a phase 3 study. *Cardiovasc Drugs Ther*. 2010 (published online).

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiat Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. *N Engl J Med*. 2016 Aug 4;375(5):422-34.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced non-squamous non-small-cell lung cancer. *J Clin Oncol*. 2015 Feb 10;33(5):433-41.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. *J Clin Oncol*. 2015 Jan 10;33(2):172-9.

O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. *Clin Colorectal Cancer*. 2014 Sep;13(3):156-163.

Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). *Cancer Chemother Pharmacol*. 2014 Jul;74(1):37-43.

Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). *Arterioscler Thromb Vasc Biol*. 2014 Jun;34(6):1298-306.

Chiu YL, Lorusso P, Hosmane B, Ricker JL, Awni W, Carlson DM. Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors. *Cancer Chemother Pharmacol*. 2014 Jan;73(1):213-7.

Chiu YL, Carlson DM, Pradhan RS, Ricker JL. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma. *Clin Ther*. 2013 Nov;35(11):1770-7.

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. *Clin Ther*. 2013 Aug;35(8):1186-98.

Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. *Clin Cardiol*. 2010 Oct;33(10):609-19.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2011 Aug;6(8):1418-25.

Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Eur J Cancer. 2011 Dec;47(18):2706-14.

Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, Dudley M, Glaser K, McKeegan E, Albert DH, Li X, Pradhan R, Stock W. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Leuk Lymphoma. 2012 Aug;53(8):1543-51.

Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86.

Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Cardiovasc Drugs Ther. 2012 Aug;26(4):349-58.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Cancer. 2013 Jan 15;119(2):380-7.

Abstracts:

Carlson D, Carley D, McGee T, James T, Önal E, Lopata M, Basner R. Levator veli palatini and genioglossus interaction in partitioning oronasal airflow.
American Review of Respiratory Disease. 145: A409, 1992.

Applebaum R, James T, Zhang Y, Carlson D, Basner R, Önal E, Lopata M, Carley D. Effects of inhaled CO₂ on respiratory response to brief cortical arousal.
American Review of Respiratory Disease. 145: A404, 1992.

Carley DW, Applebaum R, Zhang Y, James T, Carlson D, Basner R, Önal E, Lopata M. Effects of short lasting subcortical arousal on respiratory pattern.
American Review of Respiratory Disease. 145: A403, 1992.

Carlson DM, Nepomuceno DJ, Sullivan L, Tobin MJ. Inspiratory oronasal partitioning and upper airway muscle activity in obstructive sleep apnea syndrome.
American Journal of Respiratory and Critical Care Medicine. 153: A, 1996.

Nepomuceno DJ, Sullivan L, Carlson DM. Effect of external nasal dilator on upper airway resistance.
American Journal of Respiratory and Critical Care Medicine, 155: A677, 1997.

Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight R, McKeegan E, Carlson D, Cernohous P, and Figlin R. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. Proceedings of the American Society of Clinical Oncology, 23(17s): 404s, 2005. (abstract 4607)

Baker L, Demetri G, Mendelson D, Rowinsky E, McKeegan E, Knight R, Carlson D, Cernohous P, and Lobell M. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma. Proceedings of the American Society of Clinical Oncology, 23(17s): 819s, 2005. (abstract 9013).

Carlson D, McKeegan E, Rogers J, Knight R, Hippensteel R, and Figlin R. Baseline circulating endothelial cell number as prognostic markers in a phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with untreated advanced renal cell carcinoma (RCC). The Fourth International Kidney Cancer Symposium. October 2005, Chicago. (Abstract and oral presentation)

Levine A, Schwartzberg L, Smith S, Belt R, Knight R, Carlson D, Hippensteel R, and Kahl B. A phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with refractory lymphoma. Meeting Proceedings of the American Society of Hematology (Abstract 1493); Atlanta, GA. December 2005.

Davidson M, Carlson D, Guthrie R, Kelly M, Lele A, Setze C, Sleep D. ABT-335 in combination with rosuvastatin improves multiple lipid ratios in patients with mixed dyslipidemia [NLA Abstract 206]. J Clin Lipidol 2008;2(3):211.

Jones P, Carlson D, Dayspring T, Kelly M, Lele A, Setze C, Sleep D. Effects of ABT-335 in combination with rosuvastatin on low-density lipoprotein particle size in patients with mixed dyslipidemia [NLA Abstract 215]. J Clin Lipidol 2008;2(3):219.

Davidson MH, Fraser N, O'Mahony M, Kelly MT, Setze CM, Lele A, Carlson DM, Sleep DJ. Effects of ABT-335 (Fenofibric Acid) in combination with rosuvastatin on c-reactive protein levels in patients with mixed dyslipidemia. Abstract. Lorenzini Symposium on Integrated Biomarkers in Cardiovascular Disease. Seattle, Washington, 9 July 2008.

Davidson MH, Jones PH, Lele A, Carlson DM, Setze CM, Kelly MT, Sleep DJ. Simultaneous achievement of optimal lipid levels with the combination of ABT-335 (Fenofibric Acid) and rosuvastatin in patients with mixed dyslipidemia. Annual Scientific Sessions. American Heart Association. November 2008, New Orleans.

Steinberg J, Ricker JL, Wong YN, Tan EH, Toh HC, Kollmannsberger CK, Qian J, Ashton E, Carlson D. ABT-869 response monitoring with DCE-MRI, PET and CT imaging in advanced solid tumor cancer patients. Proc Amer Assoc Cancer Res. 2009: #5629.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Steinberg J, Ricker JL, Carlson DM, Qian J, Qin Q, Yong WP. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(15S) May 20 Supplement: Abs 4581.

Tan EH, Salgia R, Besse B, Goss G, Gandara DR, Hanna N, Steinberg J, Ricker JL, Qian J, Carlson DM, Mazieres J, Soo R. ABT-869 is active in non small cell lung cancer (NSCLC): Interim results.
J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(15S) May 20 Supplement: Abs 8074.

Tannir N, Wong Y, Kollmannsberger C, Ernstoff D, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: efficacy and safety results.
J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009;27(15S) May 20 Supplement: Abs 5036.

Tan EH, Goss G, Salgia R, Besse B, Gandara DR, Hanna N, Ricker JL, Qian J, Carlson DM, Soo R. Phase II results of ABT-869 treatment in patients with non-small cell lung cancer (NSCLC).
European Journal of Cancer Supplements. Sep 2009;7(2):509.

Toh HC, Chen P, Knox JJ, Gill S, Carlson DM, Qian J, Qin Q, Ricker JL, Yong WP. International phase 2 trial of linifanib (ABT-869) in patients with advanced hepatocellular carcinoma (HCC).
European Journal of Cancer Supplements. Sep 2009;7(2):366.

Tannir N, Wong YN, Kollmannsberger C, Ernstoff M, Perry D, Appleman L, Posadas E, Qian J, Ricker JL, Michaelson MD. Phase 2 results of linifanib (ABT-869) treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure.
European Journal of Cancer Supplements. Sep 2009;7(2):425.

Yong WP, Chen PJ, Knox J, et al. Open-label, multicenter phase 2 trial of linifanib (ABT-869) in advanced hepatocellular carcinoma (HCC) patients: prognostic factors.
Oral presentation at: ILCA, Milan, Italy, 6 September 2009. Abstract O-034.

Rugo H, Lopez-Hernandez J, Gomez-Villanueva A, et al. Linifanib (ABT-869) in combination with paclitaxel as first-line treatment in patients with advanced breast cancer.
Poster presented at: SABCS in San Antonio, TX on 12 December 2009.

Gupta N, Palaparthi R, Awni W, Carlson DM, Pradhan R. Study M10-310: Carboplatin/paclitaxel in combination with linifanib (ABT-869) versus carboplatin/paclitaxel alone in patients with advanced or metastatic non-small cell lung cancer (NSCLC) as first-line treatment.
J Thoracic Oncol. Sep 2009;4(9, S1): S669, abstr P1.153.

Ramalingam S, Owonikoko T, Khuri F, Saba N, Wallace J, Qian J, Gupta N, Ricker JL, Carlson DM. Phase 2 study of linifanib (ABT-869) in combination with carboplatin/ paclitaxel (CP) in patients with advanced or metastatic non-small cell lung cancer (NSCLC): lead-in cohort results.
J Thoracic Oncol. Sep 2009;4(9, S1): S706, abstr P1.234.

Tamura T, Noboru Y, Hiroshi N, et al. A Phase I Open-Label Study Evaluating Pharmacokinetics (PK), Safety and Tolerability of Linifanib (ABT-869) in Japanese Patients with Solid Tumors.
Poster presented at: AACR-NCI-EORTC in Boston, MA on 18 November 2009.

Gupta N, Yan Z, LoRusso P, et al. Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib.
Poster presented at: AACR-NCI-EORTC in Boston, MA on 17 November 2009.

Goldberg AC, Wenger NK, Carlson DM, Kelly MT, Setze CM, Gold A, Cressman M, Stolzenbach JC, Williams LA. Efficacy and safety of fenofibric acid and rosuvastatin combination therapy in women 55 years or older (post-menopausal) with mixed dyslipidemia. NLA'09 annual conference in Miami, FL.

Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Cressman M, Stolzenbach JC, Williams LA. Fenofibric acid in combination with rosuvastatin 5, 10, or 20 mg improves the atherogenic lipid profile in patients \geq 65 years with mixed dyslipidemia. NLA '09 annual conference in Miami, FL

Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib in patients with advanced hepatocellular carcinoma (HCC). Oral presentation O-015. International Liver Cancer Association (ILCA) annual meeting, Montreal, CA, September 2010.

Ansell PJ, Toh H, Chen P, Carr B, Knox JJ, Gill S, Yong WP, Qian J, Ricker JL, Carlson DM, Chan S, Dowell B, McKeegan EM. Phase 2 trial of linifanib (ABT-869) in advanced hepatocellular carcinoma (HCC): association of biomarkers to patient outcomes. International Liver Cancer Association (ILCA) annual meeting, Montreal, CA, September 2010.

Toh HC, Chen PJ, Knox J, Gill S, Kang Y, Qian J, Qin Q, Gupta N, Pradhan R, Ricker JL, McKee MD, Carlson DM, Yong WP. International phase 2 trial of linifanib (ABT-869) in patients with advanced Hepatocellular carcinoma (HCC): analysis by Chinese and non-Chinese ethnicity. Oral presentation at: CSCO, 2010.

Tan EH, Goss G, Salgia R, et al. A phase 2 trial of linifanib treatment in non-small cell lung cancer (NSCLC) patients. *Annals Oncol.* 2010;21(suppl 8): abstr 416. doi:10.1093/annonc/mdq518 | viii139.

O'Neil BH, Karapetis CS, Goff LW, Gupta N, Pradhan R, Qin Q, Ricker JL, McKee MD, Carlson DM, Goldberg RM, Berlin JD. Combination therapy with linifanib (ABT-869) and mFOLFOX6 for patients with metastatic colorectal cancer. ESMO-GI. 2010.

Toh HC, Yong WP, Wong Y, Tan E, Kollmannsberger CK, Devanarayan V, Zhang K, Luo Y, Chen D, Ashton E, Ricker JL, Carlson D, Chen P. Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: associations of response by CT or DCE-MRI with patient outcome. AACR-NCI-EORTC poster presentation 2009.

Yong W, Toh H, Knox JJ, Gill S, Chen D, Fox G, Carlson D, Zhang K, Devanarayan V, Luo Y, Ricker JL, Chen P. Phase 2 trial of linifanib (ABT-869) in advanced hepatocellular carcinoma: associations of response by CT or DCE-MRI with patient outcome. International Liver Cancer Association (ILCA) annual meeting 2009; Milan, Italy.

Chiu Y-L, Yan Z, Gupta N, Diderichsen PM, Carlson D, Pradhan R, Awni W. Exposure-response analysis to identify linifanib dose in hepatocellular carcinoma patients. ECCO-ESMO 2009.

Gupta N, Chiu Y-L, Toh HC, Chen PJ, Yong WP, McKee MD, Ricker JL, Carlson D, Pradhan R. Preliminary pharmacokinetics and safety comparison of Child-Pugh A vs. Child-Pugh B patients enrolled in a phase 2 study of linifanib (ABT-869) in hepatocellular carcinoma.

ESMO 2010, Milan Italy.

Goh, BC, Wong CI, Qian J, McKeegan EM, Gupta N, Ricker JL, Carlson DM, Soo R.
Extended linifanib therapy in patients with advanced solid tumors in a phase 1 trial.
ASCO 2010, Chicago, IL.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, McKeegan M, Dowell B, Qian J, Qin Q, Ricker JL,
Carlson DM, Yong WP. Linifanib phase 2 trial in patients with advanced hepatocellular carcinoma
(HCC).
ASCO 2010, Chicago, IL.

Soo R, Goss G, Salgia R, Besse B, Gandara DR, Hanna N, Ricker JL, Qian J, Carlson DM, Tan EH.
Linifanib treatment in patients with non-small cell lung cancer (NSCLC): phase 2 results.
ASCO 2010, Chicago, IL.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Qian J, Qin Q, McKee MD, Ricker JL, Carlson DM,
Yong WP. Linifanib in advanced hepatocellular carcinoma (HCC) patients: a phase 2 trial.
AASLD 2010.

Other

Co-Director of PERI “Premarketing Clinical Drug Safety and Risk Assessment” course
November 7-8, 2005, Arlington, Virginia.

Steering Committee Member, Members in Industry NetWork
American College of Chest Physicians 2002 – Present;
Vice Chair, October 2006 – 2008.

Chest 2007 Annual Meeting. Chaired and presented at session entitled:
Contemplating a Career Change: Alternative Careers in Industry.
October 23, 2007.

Chest 2006 Members in Industry Postgraduate Course:
Setting Up a Clinical Investigational Site: Safety Reporting
October 21, 2006.

Chest 2005 Annual Meeting
Opportunities in the Pharmaceutical Industry: Safety Officers
November 2005.

ACCP Physician Members in Industry update article
March 2007.

Understanding Endometriosis: Current Trends and Future Management.
<https://innovation.org/diseases/miscellaneous/endometriosis/understanding-endometriosis-current-trends-future-management>
April 2017.

PhRMA Go Boldly Campaign—JIA. <https://innovation.org/diseases/autoimmune/juvenile-arthritis>